Key result
Up-regulation of carbonyl reductase 1 (CBR1) promotes doxorubicin resistance in gastrointestinal cancer cells, which can be reversed by the specific CBR1 inhibitor quercetin.
Why the study?
Does modulation of Carbonyl Reductase 1 (CBR1) alter doxorubicin resistance in human gastrointestinal cancer cells?
Does modulation of Carbonyl Reductase 1 (CBR1) alter doxorubicin resistance in human gastrointestinal cancer cells?
CBR1 promotes doxorubicin resistance in gastrointestinal cancer cells likely through detoxification of cytotoxic aldehydes, suggesting CBR1 inhibitors could be useful in adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for CBR1 inhibition to overcome doxorubicin resistance in GI cancers; prospective trials needed before clinical adoption.
Matsunaga et al. (2015) studied Gastrointestinal cancers. Carbonyl reductase 1 (CBR1) modulation and Quercetin vs. Parental cells or vehicle control was evaluated on Doxorubicin resistance (cell viability/LD50). Up-regulation of carbonyl reductase 1 (CBR1) promotes doxorubicin resistance in gastrointestinal cancer cells, which can be reversed by the specific CBR1 inhibitor quercetin.